
Leqembi Becomes Europe’s First Alzheimer’s Antibody
The European Union authorizes Leqembi as its very first Alzheimer’s drug to target an underlying cause of Alzheimer’s.
The European Union authorizes Leqembi as its very first Alzheimer’s drug to target an underlying cause of Alzheimer’s.
The new Alzheimer’s antibodies, Leqembi and Kisunla, work better on some people than others. A cutting-edge technique called spatial transcriptomics may help figure out how to make them work better for everybody.
ARTICLE + VIDEO INFOMMERCIAL: Namazaric for dementia comes in a convenient, extended-release capsule. It conveniently combines today’s 2 most popular drugs for Alzheimer’s. Learn about easy-to-manage Namazaric.
A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.
The EMA has announced its schedule for reviewing the Alzheimer’s drug Leqembi (lecanemab) for use in Europe. Meanwhile, the U.S. FDA, which already approved the drug, is moving ahead with a new version that doses Leqembi in a better, more convenient fashion for those taking the drug over the long run.
Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.
Leqembi and Kisunla are the new Alzheimer’s immunotherapies. A loss of brain volume associated with these immunotherapies may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue. A new study sheds light on what’s going on.
Europe originally said Lecanemab (Brand-name Leqembi) was too risky to approve. Now they are recommending marketing it. Why the change of heart?
The European Medicines Agency (EMA) recommended approving Leqembi® (generic lecanemab) for Alzheimer’s. Originally skeptics, learn how the “Clarity AD” trial helped change their mind.
Leqembi is an FDA-Approved Alzheimer’s treatment. Hospital infusions take an hour each. 2025 is looking to see a new 15-second autoinjector version. For some, it should even work at home.
There is a choice we make when a loved one gets Alzheimer’s. Walk away, or don’t walk away. Marilyn’s Mom told her to walk away. Marilyn chose not to. She’s glad she didn’t. Share her journey.
Anyone can give up,
It’s the easiest thing in the world to do.
But to hold it together
When everyone else would understand
If you fell apart,
That’s true strength.
Sugar, the brain, and Alzheimer’s – just how tight is their connection? Check out this update from Tulane University’s targeted study.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
No spam, only news and updates.